Phaseline

Companies › Antares Therapeutics

Antares Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATX-898–Phase 1Advanced Solid TumorsOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07767474ATX-898Phase 1Advanced Solid TumorsOncologyOct 2029

From the company's SEC filings

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.